Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome

Fertility and Sterility

Volumn 81, Issue 3, 2004, Pages 624-629

  Belli, Susana H ^a   Graffigna, Mabel N ^a   Oneto, Adriana ^a   Otero, Patricia ^a   Schurman, Leon ^b   Levalle, Oscar A ^a  

^a HOSPITAL DURAND   (Argentina)

^b Tomografia Computada Buenos Aires TCBA   (Argentina)

Author keywords

IGF 1; IGFBP 1; Insulin; Insulin resistance; Insulin sensitizing agents; Polycystic ovary syndrome; Rosiglitazone

Indexed keywords

FOLLITROPIN; GLUCOSE; GROWTH FACTOR; HYDROXYPROGESTERONE; INSULIN; LEPTIN; LUTEINIZING HORMONE; ROSIGLITAZONE; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TESTOSTERONE;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; B LYMPHOCYTE; BLOOD LEVEL; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; FOLLITROPIN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GYNECOLOGIC DISEASE; HORMONE DETERMINATION; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LUTEINIZING HORMONE BLOOD LEVEL; LYMPHOCYTE FUNCTION; MENSTRUATION; ORAL GLUCOSE TOLERANCE TEST; OUTPATIENT; OVARY POLYCYSTIC DISEASE; PREGNANCY; PRIORITY JOURNAL; PROSPECTIVE STUDY; STANDARDIZATION; TESTOSTERONE BLOOD LEVEL;

ADOLESCENT; ADULT; BODY MASS INDEX; FEMALE; GLUCOSE TOLERANCE TEST; GROWTH SUBSTANCES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; INSULIN-LIKE GROWTH FACTOR I; LUTEINIZING HORMONE; MENSTRUATION; POLYCYSTIC OVARY SYNDROME; PREGNANCY; PROSPECTIVE STUDIES; REPRODUCTION; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 1642297316     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2003.08.024     Document Type: Article

References (50)

1. Zawadzki J., Dunaif A. Diagnostic criteria for polycystic ovary syndrome towards a rational approach. Dunaif A., Givens J., Haseltine F., Merriam G.R. Polycystic ovary syndrome. 1992;377-384 Blackwell Scientific, Oxford.
2. Knochenhauer E., Key T., Kashar-Miller M., Waggoner W., Boots L.R., Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the Southeastern United States a prospective study. J Clin Endocrinol Metab. 83:1998;3078-3082.
3. Asunción M., Calvo R.M., San Millán J.L., Sancho J., Avila S., Escobar-Morreale H.F. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab. 85:2000;2434-2438.
4. Franks S. Polycystic ovary syndrome. N Engl J Med. 333:1995;853-861.
5. Dunaif A. Insulin resistance and the polycystic ovary syndrome mechanism and implications for pathogenesis. Endocrin Rev. 18:1997;774-800.
6. Barbieri R.L., Makris S., Randall R.W., Daniels G., Kristner R.W., Ryan K.J. Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. J Clin Endocrinol Metab. 62:1986;904-910.
7. Nestler J.E., Powers L.P., Matt D.W. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 72:1991;83-89.
8. Nestler J., Barlascini C., Matt D.W., Steingolg K., Plymate S., Clore J. Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 68:1989;1027-1032.
9. Prelevic G., Wurzburger M., Balint-Peric L., Nesic J. Inhibitory effect of sandostatin on luteinizing hormone and ovarian steroids in polycystic ovary syndrome. Lancet. 336:1990;900-903.
10. Adashi E. Intraovarian regulation the proposed role of insulin-like growth factors. Ann NY Acad Sci. 687:1993;10-12.
11. Erickson G., Magoffin D., Cragun R., Chang R. The effects of insulin and insulin-like growth factors-I and II on estradiol production by granulosa cells of polycystic ovaries. J Clin Endocrinol Metab. 70:1990;894-902.
12. Bergh C., Carlsson B., Olsson J.H., Selleskog U., Hillensjo T. Regulation of androgen production in cultured human thecal cells by insulin-like growth factor-1 and insulin. Fertil Steril. 59:1993;323-331.
13. Cara J., Rosenfield R. Insulin-like growth factor-1 and insulin potentiate luteinizing hormone-induced androgen synthesis by rat ovarian thecal-interstitial cells. Endocrinology. 123:1988;733-739.
14. Hormburg R., Orvieto R., Bar-Hava I., Ben-Rafael Z. Serum levels of insulin-like growth factor-1, IGFBP-1 and insulin and the response to human menopausal gonadotrophins in women with polycystic ovary syndrome. Hum Reprod. 11:1996;716-719.
15. Kiddy D., Hamilton-Fairley D., Bush A., Short F., Anyaoku V., Reed M. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 36:1992;105-111.
16. Velazquez E., Mendoza S., Hamer T., Sosa F., Glueck C. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia and systolic blood pressure while facilitating normal menses and pregnancy. Metabolism. 43:1994;647-654.
17. Pasquali R., Gambineri A., Biscotti D., Vicennati V., Gagliardi L., Colitta D., et al. Effect of long term treatment with metformin added to hypocaloric diet on body composition, fat distribution and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab. 85:2000;2767-2774.
18. Moghetti P., Castello R., Negri C., Tosi F., Perrone F., Caputo M., et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome a randomized, double blind, placebo-controlled 6 month trial, followed by open, long term clinical evaluation. J Clin Endocrinol Metab. 85:2000;139-146.
19. Dunaif A., Scott D., Finegood D., Quintana B., Whitcomb R. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab. 81:1996;3299-3306.
20. Azziz R., Ehrmann D., Legro R., Whitcomb R., Hanley R., Fereshetian A., et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab. 86:2001;1626-1632.
21. Barman Balfout A., Plosker G.L. Rosiglitazona. Drugs. 57:1999;921-930.
22. Campbell P.J., Gerich J.E. Impact of obesity on insulin action in volunteers with normal glucose tolerance demonstration of a threshold for the adverse effect of obesity. J Clin Endocrinol Metab. 70:1990;1114-1118.
23. Marsden P.J., Murdoch A.P., Taylor R. Tissue insulin sensitivity and body weight in polycystic ovary syndrome. Clin Endocrinol. 55:2001;191-199.
24. Haffner S.M., Stern M.P., Hazuda H.P., Pugh J.A., Patterson J.K. Hyperinsulinemia in a population at high risk for non-insulin-dependent diabetes mellitus. N Engl J Med. 315:1986;220-224.
25. Haffner S.M., Miettinen H., Stern M.P. The homeostasis model in the San Antonio Heart Study. Diabetes Care. 20:1997;1087-1092.
26. Katz A., Nambi S., Mather K., Baron A., Follmann D., Sullivan G., et al. Quantitative insulin sensitivity check index a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 85:2000;2402-2410.
27. Dunaif A., Segal K., Futterweit W., Dobrjansky A. Profound peripheral insulin resistance independent of obesity in polycystic ovary syndrome. Diabetes. 38:1989;1165-1174.
28. Marsden P., Murdoch A., Taylor R. Severe impairment of insulin action in adipocytes from amenorrhoeic subjects with polycystic ovary syndrome. Metabolism. 43:1994;1536-1542.
29. Vema S., Mather K., Dumont A., Anderson T. Pharmacological modulation of insulin resistance and hyperinsulinemia in polycystic ovary syndrome the emerging role. Endocrinologist. 8:1998;418-424.
30. Kowalska I., Kinalski M., Stroczkowski, Wolczynski S., Kinalska I. Insulin, leptin, IGF-1 and insulin-dependent protein concentrations after insulin-sensitizing therapy in obese women with polycystic ovary syndrome. Eur J Endocrinol. 144:2001;509-515.
31. Lebovitz H., Dole J., Patwardhan R., Rappaport E., Freed M. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab. 86:2001;280-288.
32. Ikeda Y., Suehiro T., Nakamura T., Kumon Y., Hashimoto K. Clinical significance of the insulin resistance index assessed by homeostasis model assessment. Endocrin J. 48:2001;81-86.
33. Hermans M., Levy J., Morris R., Turner R. Comparison of insulin sensitivity tests across a range of glucose tolerance from normal to diabetes. Diabetología. 42:1999;678-687.
34. Hrebicek J., Janout V., Malincikova J., Horakova D., Cizek L. Detection of insulin resistance by simple quantitative insulin sensitivity check index QUICKI for epidemiological assessment and prevention. J Clin Endocrinol Metab. 87:2002;144.
35. Erhmann D.A., Cavaghan M.K., Imperial J., Sturis J., Rosenfield R.L., Polonsky K.S. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 82:1997;524-530.
36. De Fronzo R.A. Pathogenesis of type II diabetes: implications for metformin. Drugs. 58:(Suppl 1):1999;29-30.
37. Ehrmann D., Schneider D., Sobel B., Cavaghan M., Imperial J., Rosenfield R., et al. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 82:1997;2108-2116.
38. Pasquali R. The endocrine impact of obesity in eumenorrheic women. Azziz R., Nestler J.E., Dewailly D. Androgen excess disorders in women. 1997;507-518 Lippincott-Raven Publishers, Philadelphia.
39. Morales A., Laughlin G., Butzow T., Maheshwari H., Baumann G., Yen S. Insulin, somatotrophic and luteinizing hormone axes in lean and obese women with polycystic ovarian syndrome common and distinct features. J Clin Endocrinol Metab. 81:1996;2854-2864.
40. Kolaczynski J., Considine R., Ohannesian J., Marco C., Opentanova I., Nyce M., et al. Responses of leptin to short term fasting and refeeding in humans a link with ketogenesis but not ketones themselves. Diabetes. 45:1996;1511-1515.
41. De Leo V., La Marca R., Orvieto R., Morgante G. Effect of metformin on insulin-like growth factor (IGF) l and IGF-binding protein l in polycystic ovary syndrome. J Clin Endocrinol Metab. 85:2000;1598-1600.
42. Morin-Papunen L., Vauhkonen I., Koivunen R., Ruokonen A., Martikainen H., Tapanainen J. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome a randomized study. J Clin Endocrinol Metab. 85:2000;3161-3168.
43. Erickson G., Garzo V., Magoffin D. Insulin-like growth factor l (IGF-l) regulates aromatasa activity in human granulosa and granulosa luteal cells. J Clin Endocrinol Metab. 69:1989;716-724.
44. Apter D., Bützow T., Laughlin G., Yen S. Metabolic features of polycystic ovary syndrome are found in adolescent girls with hyperandrogenism. J Clin Endocrinol Metab. 80:1995;2966-2973.
45. Stivel M, García Arias G, Otero P, Oneto A. Insulin, IGF-1 and IGF binding proteins in hyperandrogenic adolescents [abstract 558, miniposter 9]. Program and abstracts of the 5th Joint Meeting of the European Society for Paediatric Endocrinology (ESPE) and Lawson Wilkins Paediatric Endocrine Society. Stockholm, 1997
46. Mason H., Cwyfan-Hughes S., Heinrich G., Franks S., Holly J. Insulin-like growth factor (IGF) I and II, IGF binding proteins and IGF-binding protein proteases are produced by theca and stroma of normal and polycystic ovaries. J Clin Endocrinol Metab. 81:1996;276-284.
47. Veldhuis J., Zhang G., Garmey J. Troglitazone, an insulin-sensitizing thiazolidinedione, represses combined stimulation by LH and insulin of de novo androgen biosynthesis by thecal cells in vitro. J Clin Endocrinol Metab. 87:2002;1129-1133.
48. Ghazeeri G., Kutteh W.H., Bryer-Ash M., Haas D., Ke R.W. Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome. Fertil Steril. 79:2003;562-566.
49. Shobokshi A., Shaarawy M. Correction of insulin resistance and hyperandrogenism in polycystic ovary syndrome by combined rosiglitazone and clomiphene citrate therapy. J Soc Gynecol Investig. 10:2003;99-104.
50. Cataldo N., Abassi F., McLaughlin T., Lamendola C., Reaven G. Improvement in insulin sensitivity followed by ovulation and pregnancy in a woman with polycystic ovary syndrome who was treated with rosiglitazone. Fertil Steril. 5:2001;1057-1059.